{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:39:06Z","timestamp":1793090346431,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105575","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:24:03Z","timestamp":1788881043000},"page":"105575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Predictive biomarkers in cancer immunotherapy for genitourinary malignancies"],"prefix":"10.1016","volume":"227","author":[{"given":"Alexandra","family":"Paulet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Shtembari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Izzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Calandrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella Micol","family":"Mela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1674-6312","authenticated-orcid":false,"given":"Roberta","family":"Giorgione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Pillozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5504-8237","authenticated-orcid":false,"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105575_bib1","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"54","author":"Abida","year":"2019","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105575_bib2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","article-title":"Liquid biopsy: from discovery to clinical application","volume":"11","author":"Alix-Panabi\u00e8res","year":"2021","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105575_bib3","doi-asserted-by":"crossref","DOI":"10.1200\/PO-24-00667","article-title":"Longitudinal testing of circulating tumor DNA in patients with metastatic renal cell carcinoma","author":"Basu","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105575_bib4","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105575_bib5","first-page":"11","article-title":"Cancer-specific thresholds adjust for whole exome sequencing\u2013based tumor mutational burden distribution","author":"Chalmers","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105575_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100305","article-title":"Blood and urine-based biomarkers in prostate cancer: current advances, clinical applications, and future directions","volume":"9","author":"Crocetto","year":"2025","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.critrevonc.2026.105575_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2026.156372","article-title":"PD-L1 expression across urothelial carcinoma subtypes: a multicenter comparison of 22C3 and SP142 for clinical decision-making in the immunotherapy era","volume":"281","author":"Cuadra","year":"2026","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.critrevonc.2026.105575_bib8","doi-asserted-by":"crossref","DOI":"10.1007\/s11255-025-04912-5","article-title":"Artificial intelligence and multi-omics integration in liquid biopsy for genitourinary cancers: a systematic scoping review","author":"Eskandar","year":"2025","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.critrevonc.2026.105575_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104862","article-title":"Emerging biomarkers in bladder cancer: translating molecular advances into precision oncology","volume":"215","author":"Ferro","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105575_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1192762","article-title":"Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis","volume":"10","author":"Fitzsimmons","year":"2023","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105575_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100118","article-title":"Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort","volume":"6","author":"Fornarini","year":"2021","journal-title":"ESMO Open."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105575_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010311","article-title":"Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types","volume":"13","author":"Gandara","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105575_bib13","article-title":"PD-1 blockade plus tyrosine kinase inhibitor remodels the tumor microenvironment in advanced renal cell carcinoma","author":"Gu","year":"2026","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105575_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2024.10.016","article-title":"Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade","volume":"42","author":"Hamidi","year":"2024","journal-title":"Cancer Cell."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105575_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105575_bib16","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105575_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12943-024-02040-9","article-title":"Advances in spatial transcriptomics and its applications in cancer research","volume":"23","author":"Jin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105575_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1506278","article-title":"The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers","volume":"16","author":"Kalemoglu","year":"2025","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105575_bib19","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.3390\/ijms20071692","article-title":"Targeting the PD-1\/PD-L1 pathway in renal cell carcinoma","volume":"20","author":"Kammerer-Jacquet","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105575_bib20","first-page":"441","article-title":"Radiomics: extracting more information from medical images using advanced feature analysis","volume":"48","author":"Lambin","year":"2012","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105575_bib21","doi-asserted-by":"crossref","first-page":"C1417","DOI":"10.1152\/ajpcell.00255.2022","article-title":"The convergence of tumor suppressors on the type I interferon pathway in clear cell renal cell carcinoma and its therapeutic implications","volume":"323","author":"Langbein","year":"2022","journal-title":"Am. J. Physiol. -Cell. Physiol. novembre"},{"key":"10.1016\/j.critrevonc.2026.105575_bib22","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231189436","article-title":"Immune gene signatures as prognostic criteria for cancer patients","volume":"15","author":"Larionova","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"6349","key":"10.1016\/j.critrevonc.2026.105575_bib23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105575_bib24","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/1078-0432.CCR-23-3403","article-title":"Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer","volume":"30","author":"Lenis","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105575_bib25","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2486592","article-title":"Elevated circulating IL-8 correlates with poor prognosis in urological cancers: a meta-analysis and bioinformatic validation","volume":"57","author":"Lin","year":"2025","journal-title":"Ann. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105575_bib26","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1097\/JS9.0000000000001372","article-title":"Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis","volume":"110","author":"Liu","year":"2024","journal-title":"Int. J. Surg."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105575_bib27","first-page":"2293","article-title":"Applications of radiomics in genitourinary tumors","volume":"10","author":"Liu","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105575_bib28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1158\/1078-0432.CCR-20-3877","article-title":"CDK12 deficiency and the immune microenvironment in prostate cancer","volume":"27","author":"Lotan","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105575_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1215","article-title":"Significance of PD-L1 in metastatic urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"7","author":"Maiorano","year":"2024","journal-title":"JAMA Netw. Open."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105575_bib30","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.3390\/jcm12154987","article-title":"Biomarkers for immune checkpoint inhibitors in renal cell carcinoma","volume":"12","author":"Martin","year":"2023","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105575_bib31","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.3390\/cancers17091408","article-title":"Advancing cancer treatment: a review of immune checkpoint inhibitors and combination strategies","volume":"17","author":"Mc Neil","year":"2025","journal-title":"Cancers"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105575_bib32","doi-asserted-by":"crossref","first-page":"9550","DOI":"10.3390\/ijms22179550","article-title":"The role of somatic mutations on the immune response of the tumor microenvironment in prostate cancer","volume":"22","author":"Melo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105575_bib33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell."},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105575_bib34","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105575_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1629001","article-title":"Revealing intra-group immunotherapy response heterogeneity in metastatic urothelial carcinoma through interpretable feature extraction and spectral clustering","volume":"16","author":"Nagumo","year":"2026","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105575_bib36","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1158\/1078-0432.CCR-24-0400","article-title":"Evaluating immune checkpoint blockade in metastatic castration-resistant prostate cancers with deleterious CDK12 alterations in the phase 2 IMPACT trial","volume":"30","author":"Nguyen","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105575_bib37","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","article-title":"Cancer immunotherapy: it\u2019s time to better predict patients\u2019 response","volume":"125","author":"Pilard","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105575_bib38","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.urolonc.2025.07.034","article-title":"Liquid biopsy testing in urological cancers: focus on urine","volume":"43","author":"Pisapia","year":"2025","journal-title":"Urol. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105575_bib39","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.annonc.2024.05.537","article-title":"Renal cell carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2729","volume":"35","author":"Powles","year":"2024","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105575_bib40","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO clinical practice guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"E. Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105575_bib41","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1038\/s41591-024-03091-7","article-title":"Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial","volume":"30","author":"Powles","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2026.105575_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01644","article-title":"Predictive biomarkers of response to immunotherapy in metastatic renal cell cancer","volume":"10","author":"Raimondi","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105575_bib43","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1078-0432.CCR-20-2371","article-title":"Characterizing CDK12-mutated prostate cancers","volume":"27","author":"Rescigno","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105575_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102558","article-title":"Clinico-pathological implications of the 2022 WHO renal cell carcinoma classification","volume":"116","author":"Rizzo","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105575_bib45","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.clgc.2021.03.012","article-title":"Three-dimensional deep noninvasive radiomics for the prediction of disease control in patients with metastatic urothelial carcinoma treated with immunotherapy","volume":"19","author":"Rundo","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105575_bib46","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13046-022-02469-0","article-title":"The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy","volume":"41","author":"Shi","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105575_bib47","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12672-025-02128-8","article-title":"Review of recent molecular pathology of bladder urothelial carcinoma","volume":"16","author":"Su","year":"2025","journal-title":"Discov. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105575_bib48","doi-asserted-by":"crossref","first-page":"e731","DOI":"10.1016\/S1470-2045(17)30607-1","article-title":"De-novo and acquired resistance to immune checkpoint targeting","volume":"18","author":"Syn","year":"2017","journal-title":"Lancet Oncol. dicembre"},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105575_bib49","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105575_bib50","doi-asserted-by":"crossref","unstructured":"Vainer G.W., Badve S.S., Rajadurai P., Soares F.A., Viale G., B\u00fcttner R., et al. Unraveling the complexity of PD-L1 assays: a descriptive review of the methodology, scoring, and practical implications. Front Oncol. 15:1581275. doi:10.3389\/fonc.2025.1581275 PubMed PMID: 41415556; PubMed Central PMCID: PMC12710237.","DOI":"10.3389\/fonc.2025.1581275"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105575_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44103-9","article-title":"Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study","volume":"13","author":"V\u00e1radi","year":"2023","journal-title":"Sci. Rep."},{"issue":"7331","key":"10.1016\/j.critrevonc.2026.105575_bib52","first-page":"539","article-title":"Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma","volume":"469","author":"Varela","year":"2011","journal-title":"Nat. gennaio"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105575_bib53","first-page":"1595","article-title":"Clinical evidence for microbiome-based strategies in cancer immunotherapy: a state-of-the-art review","volume":"60","author":"Vivarelli","year":"2024","journal-title":"Med. (Kaunas. )"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105575_bib54","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.21037\/tcr-2024-2516","article-title":"Microsatellite instability (MSI) and the tumor mutation burden (TMB) as biomarkers of response to immune checkpoint inhibitors in prostate cancer","volume":"14","author":"Voutsadakis","year":"2025","journal-title":"Transl. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105575_bib55","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1038\/s41467-018-05992-x","article-title":"EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105575_bib56","first-page":"24173","article-title":"Recent advances and future prospects of immunotherapeutic approaches in prostate cancer","author":"Wang","year":"2026","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105575_bib57","first-page":"826","article-title":"Role of tumor microenvironment in prostate cancer immunometabolism","volume":"15","author":"Wang","year":"2025","journal-title":"Biomol. giugno"},{"key":"10.1016\/j.critrevonc.2026.105575_bib58","article-title":"Role of tumor mutational burden in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105575_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1643533","article-title":"Characteristics of the tumor microenvironment and potential immunotherapy strategies in renal cell carcinoma","volume":"16","author":"Wen","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105575_bib60","first-page":"211","article-title":"The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies","volume":"69","author":"Wilson","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105575_bib61","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41581-023-00700-5","article-title":"Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens","volume":"19","author":"Wolf","year":"2023","journal-title":"Nat. Rev. Nephrol. luglio"},{"issue":"15","key":"10.1016\/j.critrevonc.2026.105575_bib62","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.7150\/ijbs.114618","article-title":"Single-cell and spatial transcriptomic analysis reveal cellular heterogeneity and cancer cell-intrinsic major histocompatibility complex II expression in urothelial carcinoma","volume":"21","author":"Xiong","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105575_bib63","first-page":"688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"133","author":"Yang","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105575_bib64","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/cancers17030480","article-title":"Evaluating tumour mutational burden as a key biomarker in personalized cancer immunotherapy: a pan-cancer systematic review","volume":"17","author":"Zgura","year":"2025","journal-title":"Cancers gennaio"},{"key":"10.1016\/j.critrevonc.2026.105575_bib65","article-title":"Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy","volume":"14","author":"Zhang","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105575_bib66","first-page":"3721","article-title":"Development of an interferon gamma response-related signature for prediction of survival in clear cell renal cell carcinoma","volume":"15","author":"Zhang","year":"2022","journal-title":"J. Inflamm. Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105575_bib67","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13045-024-01600-2","article-title":"Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. OncolJ Hematol. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:04:50Z","timestamp":1793088290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":67,"alternative-id":["S1040842826004622"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105575","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive biomarkers in cancer immunotherapy for genitourinary malignancies","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105575"}}